BioIDEA and EVQLV are hosting a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
Biotech vs COVID-19
read more
Daniel Gigante
Andrew Satz Discusses Remote Work on the Gaper Podcast
Our CEO, Andrew Satz, has spent the last 15 years working remotely — making him a veritable expert on the skill. He was recently a guest on the Gaper podcast where he shared three methods you can quickly implement to help you adjust to remote work.
EVQLV Wins Columbia Venture Competition
EVQLV is excited to announce we took first place in Columbia Engineering’s Venture Competition (CVC). We would like to give a special thanks to all fellow companies, the wonderful judges, and of course, Columbia Engineering.
EVQLV Joins Name to Public Statement for Collaboration on COVID-19 Treatment Development
The World Health Organization (WHO), yesterday, released a public statement for collaboration on COVID-19 treatment development of which Andrew Satz (CEO, EVQLV) gladly joined his name.
Brett Averso on the AI Podcast in 26.1 Minutes
Our very own Brett Averso (CTO, EVQLV) was welcomed on the AI Podcast in 26.1 Minutes with hosts Brian Ray and Don Sheu. They discussed our work on COVID-19 with ImmunoPrecise, the benefits of a computational approach to antibody research and drug discovery, our progress as a company and a host of other topics.
EVQLV in the News: EVQLV Featured in TMR Blog
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV’s optimism on the project.
How Structurally Similar is SARS-CoV-2 to SARS?
Brett Averso (CTO, EVQLV) shows and explains the undeniable structural similarities between SARS-CoV-2 and SARS. We hope this video serves to dispel some of the myths you may have encountered during your search for answers surrounding coronavirus.
EVQLV Featured in insideBIGDATA
Our work with ImmunoPrecise on COVID-19 was covered by insideBIGDATA. They did a fantastic job covering the piece originally published by Columbia Data Science Institute, highlighting a few fantastic quotes
EVQLV Submits First Panel of Optimized Antibody Sequences
EVQLV, has submitted their first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2. These DNA sequences were generated using computational antibody design, a method which combines mathematics, statistics, and computer science to identify high-affinity antibodies.
5 AI Companies Using Epidemiology to Fight Coronavirus
In the AI vs COVID-19 battle there are three major areas where breakthroughs are needed, coming and have arrived: diagnosis, treatment and epidemiology. In this post, we focus on five companies who are using epidemiology to aid researchers and the general public in the fight against COVID-19.